Lynparza

Lynparza is a targeted cancer therapy belonging to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. It is primarily used in the treatment of certain advanced cancers associated with specific genetic mutations, most notably in breast cancer and ovarian cancer. Its development marked a significant advancement in the field of precision medicine, leveraging the concept of synthetic lethality to selectively target cancer cells with deficient DNA repair pathways. The drug is administered orally and has been the subject of extensive clinical research led by organizations like the Food and Drug Administration and the European Medicines Agency.

Medical uses

Lynparza is approved for the treatment of advanced ovarian cancer in patients with deleterious or suspected deleterious germline or somatic BRCA mutations, as detected by an approved test such as those from Myriad Genetics. It is also indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Furthermore, approvals extend to HER2-negative breast cancer with germline BRCA mutations, metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations, and as a first-line maintenance treatment in combination with bevacizumab for advanced ovarian cancer with homologous recombination deficiency. Its use is often guided by companion diagnostics and follows treatment guidelines from bodies like the National Comprehensive Cancer Network.

Adverse effects

Common adverse effects include nausea, fatigue, anemia, vomiting, and diarrhea. More serious hematological toxicities, such as myelodysplastic syndrome and acute myeloid leukemia, have been reported in a small percentage of patients. Other notable risks include pneumonitis and embryo-fetal toxicity, necessitating specific monitoring and contraceptive advice. Management of these effects often involves dose interruptions or reductions, as outlined in protocols from the American Society of Clinical Oncology. Patient support programs, like those offered by AstraZeneca, provide resources for managing treatment-related symptoms.

Pharmacology

As a PARP inhibitor, it works by blocking the activity of PARP1 and PARP2, enzymes critical for the repair of single-strand DNA breaks via the base excision repair pathway. In cancer cells with pre-existing deficiencies in homologous recombination repair, such as those harboring mutations in BRCA1 or BRCA2, this inhibition leads to an accumulation of DNA damage and synthetic lethality. The drug is metabolized primarily in the liver by cytochrome P450 enzymes, specifically CYP3A4 and CYP3A5. Pharmacokinetic studies show it is well-absorbed orally, with a terminal half-life allowing for twice-daily dosing, and its metabolism can be affected by concomitant use of strong CYP3A inhibitors like ketoconazole.

History

The compound, initially known as AZD2281, was discovered through a collaboration between researchers at KuDOS Pharmaceuticals and the University of Cambridge, building on foundational work by scientists like Steve Jackson. AstraZeneca acquired KuDOS in 2005, leading to its further clinical development. The drug received its first regulatory approval from the Food and Drug Administration in December 2014 for advanced ovarian cancer with BRCA mutations, making it the first PARP inhibitor approved in the United States. Subsequent approvals from the European Medicines Agency and other global agencies followed, expanding its indications based on pivotal trials such as SOLO-1 and OlympiAD. Its development is considered a landmark in oncogenomics.

Society and culture

Lynparza has had a substantial impact on cancer care discourse and patient advocacy, particularly within communities focused on hereditary breast and ovarian cancer syndrome. Its high cost has been a subject of debate within healthcare systems like the National Health Service and among payers such as Medicare. The drug has been featured in media reports by outlets like BBC News and discussed at major medical conferences including the American Society of Clinical Oncology Annual Meeting. Access programs have been established by AstraZeneca in various regions, and its story is often cited in discussions about the value of biomarker-driven therapy and orphan drug designation in oncology.

Category:Antineoplastic drugs Category:AstraZeneca